| EMA number | EMEA/H/C/001064 |
| ATC code | J05AP01 |
| Authorisation | 1 July 2009 |
| Withdrawn | 22 June 2021 |
| Revision | 14 |
Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1). Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).